Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function

Bone

Volumn 50, Issue 6, 2012, Pages 1406-1415

  Hu, Yu Chen ^a   Cheng, Hsiao Ling ^a   Hsieh, Bau Shan ^a   Huang, Li Wen ^b   Huang, Tzu Ching ^a   Chang, Kee Lung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ALP; Arsenic trioxide; Bone remodeling; Mineralization; Osteoblast

Indexed keywords

ALKALINE PHOSPHATASE; ARSENIC TRIOXIDE; CARBOXY TERMINAL TELOPEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MESSENGER RNA; OSTEOCALCIN; PEPTIDE; PHOSPHATE; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; SODIUM CHLORIDE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; FEMUR; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; RAT; TRABECULAR BONE; TREATMENT DURATION;

ALKALINE PHOSPHATASE; ANIMALS; ARSENICALS; BASE SEQUENCE; BONE DENSITY; BONE REMODELING; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 1 SUBUNIT; INTERLEUKIN-6; MALE; OSTEOBLASTS; OSTEOCALCIN; OXIDATIVE STRESS; OXIDES; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSCRIPTION FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84860841588     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.03.012     Document Type: Article

References (47)

1. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
2. Kumar P., Gao Q., Ning Y., Wang Z., Krebsbach P.H., Polverini P.J. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol Cancer Ther 2008, 7:2060-2069.
3. Chen G.Q., Shi X.G., Tang W., Xiong S.M., Zhu J., Cai X., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
4. Florea A.M., Busselberg D. Arsenic trioxide in environmentally and clinically relevant concentrations interacts with calcium homeostasis and induces cell type specific cell death in tumor and non-tumor cells. Toxicol Lett 2008, 179:34-42.
5. Florea A.M., Splettstoesser F., Busselberg D. Arsenic trioxide (As2O3) induced calcium signals and cytotoxicity in two human cell lines: SY-5Y neuroblastoma and 293 embryonic kidney (HEK). Toxicol Appl Pharmacol 2007, 220:292-301.
6. Lin L.M., Li B.X., Xiao J.B., Lin D.H., Yang B.F. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol 2005, 11:5633-5637.
7. Barbey J.T., Pezzullo J.C., Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003, 21:3609-3615.
8. Ishitsuka K., Shirahashi A., Iwao Y., Shishime M., Takamatsu Y., Takatsuka Y., et al. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. Eur J Haematol 2004, 72:280-284.
9. Roboz G.J., Dias S., Lam G., Lane W.J., Soignet S.L., Warrell R.P., et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525-1530.
10. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J.M., et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988, 123:2600-2602.
11. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141:3478-3484.
12. Proudfoot D., Skepper J.N., Shanahan C.M., Weissberg P.L. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 1998, 18:379-388.
13. Uchimura E., Machida H., Kotobuki N., Kihara T., Kitamura S., Ikeuchi M., et al. In-situ visualization and quantification of mineralization of cultured osteogenetic cells. Calcif Tissue Int 2003, 73:575-583.
14. Gao Y.H., Yamaguchi M. Anabolic effect of daidzein on cortical bone in tissue culture: comparison with genistein effect. Mol Cell Biochem 1999, 194:93-97.
15. Hung T.C., Huang L.W., Su S.J., Hsieh B.S., Cheng H.L., Hu Y.C., et al. Hemeoxygenase-1 expression in response to arecoline-induced oxidative stress in human umbilical vein endothelial cells. Int J Cardiol 2011, 151:187-194.
16. Cheng H.L., Su S.J., Huang L.W., Hsieh B.S., Hu Y.C., Hung T.C., et al. Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activation. Mol Cancer 2010, 9:126.
17. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
18. Hsieh B.S., Huang L.W., Su S.J., Cheng H.L., Hu Y.C., Hung T.C., et al. Combined arginine and ascorbic acid treatment induces apoptosis in the hepatoma cell line HA22T/VGH and changes in redox status involving the pentose phosphate pathway and reactive oxygen and nitrogen species. J Nutr Biochem 2011, 22:234-241.
19. Anagnostou F., Plas C., Nefussi J.R., Forest N. Role of beta-GP-derived Pi in mineralization via ecto-alkaline phosphatase in cultured fetal calvaria cells. J Cell Biochem 1996, 62:262-274.
20. Stein G.S., Lian J.B., van Wijnen A.J., Stein J.L., Montecino M., Javed A., et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004, 23:4315-4329.
21. Tanaka Y., Nakayamada S., Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:325-328.
22. Heilman K., Zilmer M., Zilmer K., Tillmann V. Lower bone mineral density in children with type 1 diabetes is associated with poor glycemic control and higher serum ICAM-1 and urinary isoprostane levels. J Bone Miner Metab 2009, 27:598-604.
23. Fernandes J.C., Shi Q., Benderdour M., Lajeunesse D., Lavigne P. An active role for soluble and membrane intercellular adhesion molecule-1 in osteoclast activity in vitro. J Bone Miner Metab 2008, 26:543-550.
24. Diaz Z., Colombo M., Mann K.K., Su H., Smith K.N., Bohle D.S., et al. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 2005, 105:1237-1245.
25. Davison K., Mann K.K., Waxman S., Miller W.H. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004, 103:3496-3502.
26. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
27. Green A.R., Gabrielsson J., Marsden C.A., Fone K.C. MDMA: on the translation from rodent to human dosing. Psychopharmacology 2009, 204:375-378.
28. Patlolla A.K., Tchounwou P.B. Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats. Mutat Res 2005, 587:126-133.
29. Hui M., Tenenbaum H.C. New face of an old enzyme: alkaline phosphatase may contribute to human tissue aging by inducing tissue hardening and calcification. Anat Rec 1998, 253:91-94.
30. Anderson H.C., Sipe J.B., Hessle L., Dhanyamraju R., Atti E., Camacho N.P., et al. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol 2004, 164:841-847.
31. Anderson H.C. Molecular biology of matrix vesicles. Clin Orthop Relat Res 1995, 266-280.
32. Kobayashi T., Kronenberg H. Minireview: transcriptional regulation in development of bone. Endocrinology 2005, 146:1012-1017.
33. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
34. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
35. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
36. Itoh K., Ishii T., Wakabayashi N., Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res 1999, 31:319-324.
37. Lee J.S., Surh Y.J. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005, 224:171-184.
38. Onodera K., Shavit J.A., Motohashi H., Katsuoka F., Akasaka J.E., Engel J.D., et al. Characterization of the murine mafF gene. J Biol Chem 1999, 274:21162-21169.
39. Hinoi E., Fujimori S., Wang L., Hojo H., Uno K., Yoneda Y. Nrf2 negatively regulates osteoblast differentiation via interfering with Runx2-dependent transcriptional activation. J Biol Chem 2006, 281:18015-18024.
40. Tanaka Y., Okada Y., Nakamura T. Inter- and intracellular signaling in secondary osteoporosis. J Bone Miner Metab 2003, 21:61-66.
41. Arron J.R., Choi Y. Bone versus immune system. Nature 2000, 408:535-536.
42. OG D., Ireland D., Bord S., Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004, 63:354-359.
43. Niki Y., Takaishi H., Takito J., Miyamoto T., Kosaki N., Matsumoto H., et al. Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction. J Immunol 2007, 179:639-646.
44. Iglesias P., Arrieta F., Pinera M., Botella-Carretero J.I., Balsa J.A., Zamarron I., et al. Serum concentrations of osteocalcin, Procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol 2011, 75:184-188.
45. Rajamanohara R., Robinson J., Rymer J., Patel R., Fogelman I., Blake G.M. The effect of weight and weight change on the long-term precision of spine and hip DXA measurements. Osteoporos Int 2011, 22:1503-1512.
46. Lee N., Radford-Smith G.L., Forwood M., Wong J., Taaffe D.R. Body composition and muscle strength as predictors of bone mineral density in Crohn's disease. J Bone Miner Metab 2009, 27:456-463.
47. Leslie W.D. Elevated bone mass: a weighty matter?. Skeletal Radiol 2008, 37:1063-1067.